{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-004426","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.626545+00:00","generated_at":"2026-06-07T02:31:01.539703+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Nuvation Bio appoints Robert Mashal, M.D. to board as Class II director","bullets":["Dr. Mashal appointed to fill vacant board seat effective Jan. 8, 2024; term expires at 2026 annual meeting.","He is a former global head of strategy for immunology/oncology at Sanofi and a board-certified medical oncologist.","Received initial option grant of $770,000 in Class A common stock vesting monthly over three years.","Also eligible for annual cash retainer of $40,000; no committee assignment as of filing date.","Board determined Dr. Mashal qualifies as independent under NYSE listing rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-004426","json":"https://secwatch.observer/filing/0001193125-24-004426.json","markdown":"https://secwatch.observer/filing/0001193125-24-004426.md","text":"https://secwatch.observer/filing/0001193125-24-004426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524004426/0001193125-24-004426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524004426/d685245d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:31:01.539703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91d5ea1e93","claim":"Robert Mashal was appointed as Director at Nuvation Bio Inc..","evidence_excerpt":"On January 8, 2024 the Board of Directors (the “ Board ”) of Nuvation Bio Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Mashal, M.D. to fill a vacant Board seat and to serve as a Class II director, with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524004426/0001193125-24-004426-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}